Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Milu Labs Signs MOU with Thermo Fisher for Women's Health Diagnostics in China

publication date: Oct 24, 2019

Milu Labs, a Philadelphia company focused on bringing diagnostics to China/Asia, signed an MOU with Thermo Fisher to develop a non-invasive test that will assess the risk of adverse pregnancy problems. The test will be built for Thermo Fisher's liquid chromatography-mass spectrometry device. Earlier this year, Milu in-licensed Asian rights to a NX Prenata liquid biopsy that tests the risk for pre-term birth. In the future, the companies plan to expand into oncology testing. More details....

Stock Symbol: (NYSE: TMO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.